期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

双磷酸盐在口腔医学方面的研究进展 被引量：3

原文传递
导出
摘要 双磷酸盐已被证实具有抑制破骨细胞的分化,促进骨形成的作用。研究发现其可以抑制颌骨吸收,影响牙齿的萌出,牙根的形成和牙齿硬组织表面形态,实验还证实双磷酸盐可促使颌骨坏死。在将双磷酸盐应用到口腔疾病治疗的同时也出现了不良反应。本文就双磷酸盐在口腔医学的研究进展作一综述。
作者 谢淑娟 潘卫红
机构地区 华中科技大学同济医学院附属协和医院口腔科
出处 《临床口腔医学杂志》 2011年第1期53-55,共3页 Journal of Clinical Stomatology
关键词 双磷酸盐 破骨细胞 牙槽骨吸收 颌骨发育
分类号 R780.2 [医药卫生—口腔医学]
  • 相关文献

参考文献20

  • 1Zahrowski JJ. Optimizing orthodontic treatment in patients taking bisphosphonates for osteoporosis [J]. Am J Orthod Dentofacial Orthop, 2009, 135 (3) : 361-374.
  • 2Ezzat BA. Validity of prevention of glueoeortieoid-induced alveolar hone loss in rat by either calcitonin or alendronate administration [J]. Arch Oral Biol, 2010, 55 (10) : 788-796.
  • 3Gao Y,Luo E,Hu J,et al. Effect of combined local treatment with zoledronic acid and basic fibroblast growth factor on implant fixation in ovariectomized rats [J]. Bone, 2009,44 (2) : 225-232.
  • 4lchimura S. Bisphosphonate [J]. Clin Calcium, 2005,15 (4) :583- 590.
  • 5Vitral RW, da Silva Campos MJ, de Andrade Vitral JC, et al. Orthodontic distalization with rigid plate fixation for anchorage after bone grafting and maxillary sinus lifting [J]. Am J Orthod Dentofacial Orthop, 2009, 136(1): 109-114.
  • 6Abtahi J, Tengvall P, Aspenberg P. Bisphosphonate coating might improve fixation of dental implants in the maxilla: A pilot study [J]. Int J Oral Maxillofac Surg, 2010, 39 (7) : 673-677.
  • 7孟海,郭艾.双磷酸盐对骨强度的影响[J].中国骨肿瘤骨病,2007,6(2):118-120. 被引量：6
  • 8Weinstein RS,Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy [J]. N Engl J Med, 2009, 360 (1) : 53-62.
  • 9Vieillard MH,Maes JM,Penel G,et al.Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy [J]. Joint Bone Spine, 2008,75 (1) : 34-40.
  • 10Ahundal H, Gtivener O. The effect of alendronate on resorption of the alveolar bone following tooth extraction [J]. Int J Oral Maxillofal Surg, 2004, 33 (3) : 286-293.

二级参考文献42

  • 1夏维波.骨重建在维持骨强度中的意义[J].中华医学杂志,2006,86(6):363-365. 被引量：13
  • 2[1]Reinholz G,Getz B,Pederson L,et al.Bisphosphonates directly regulate cell proliferation,differentiation,and gene expression in human osteoblasts.Cancer Res,2000,60:6001-6007.
  • 3[2]Rogers M,Gordon S,Benford L,et al.Cellular and molecular mechanisms of action of bisphosphonates.Cancer,2000,88(suppl):2961-2978.
  • 4[3]Rogers MJ.New insight into the molecular mechanisms of action of biosphosphonate.Curr Pharm Des,2003,9:2643-2658.
  • 5[4]Mathov I,Plotkin L,Sgarlata C,et al.Extracellular signal regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoclastic cells in vitro.J Bone Miner Res,2001,16:2050-2056.
  • 6[5]McClung M.Use of highly potent bisphosphonates in the treatment of osteoporosis.Curr Osteoporos Rep,2003,1:116-122.
  • 7[6]Cremers SC,Pillai G,Papapoulos SE.Pharmacokinetics/pharmacodynamics of bisphosphonates:use for optimization of intermittent therapy for osteoporosis.Clin Pharmacokinet,2005,44:551-570.
  • 8[7]Rubin CD,Emerging concepts in osteoporosis and bone strength.Curr Med Res Opin,2005,21:1049-1056.
  • 9[8]Sone,T,Bone structure and bone quality.Clin Calcium,2005,15:925-930.
  • 10[9]Turner CH,Biomechanics of bone deteminants of skeletal fragility and bone quality.Osteopros Int,2002,13:97-104.

共引文献8

同被引文献34

  • 1Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proe, 2008, 83(9): 1032-1045.
  • 2Cramer J, Gold D, Snverrnan S, et al. A systematic review oF persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis Int, 2007, 18(8): 1023-1031.
  • 3Bechmann G, Kriegman A, Goncalves J, et al. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postm- enopausal women with low bone density. The North American Menopause Society, 2011, 18(8): 851-856.
  • 4R? kel A, Boucher A, Georges L, et al. Role of zoledronic acid in the prevention and treatment of osteoporosis. Clinical Interventions in Aging, 2011, 6: 89-99.
  • 5Amanat N, McDonald M, Godfrey C, et al. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture re- pair. J Bone Miner Res, 2007, 22(6): 867-876.
  • 6Yanik B, Bavbek N, Yanik T, et al. The effect of alendronate, risedronate, and raloxifone on renal functions, based on the Cock-eroft and Gau|t method, in postmenopausal women. Ren Fail, 2007, 29 (4) : 471.
  • 7Hansen T, Kirkpatrick CJ, Waiter C, et ai. Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonate : associated osteonecrosis : a paradoxical observation[J].Virchows Arch, 2006, 449(4):448-454.
  • 8Kuroshima S, Go VA, Yamashita J. Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice[J]. Endocrinology, 2012,153(1):17-28.
  • 9Vigorita VJ, Silver JS, Eisemon EO. Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report[J].Skeletai Radiol, 2012, 41(7): 861-865.
  • 10Hansen T, Kunkel M, Weber A, et al. Osteonecrosis of thejaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis[J].J Oral Pathol Med, 2006, 35(3):155-160.

引证文献3

二级引证文献9

临床口腔医学杂志
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部